Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Welcome and Introduction to the Panel

F. André (France)

SlotAA-1 Introduction

Fabrice André introduces the Symposium, which addresses three questions, two about the unmet medical needs in HER2+ breast cancer, and one on the biology and new mechanisms of action for the drug.

Transcription

Welcome.  My name is Fabrice André and, together with Javier Cortés and David Cameron, we will organise this session about advanced breast cancer.  It is the end of the day and everybody is tired, so if we can make it fun and interactive, it will be better for everybody.

Disclosures

These are my disclosures.

Full transcription

Full transcription

Welcome.  My name is Fabrice André and, together with Javier Cortés and David Cameron, we will organise this session about advanced breast cancer.  It is the end of the day and everybody is tired, so if we can make it fun and interactive, it will be better for everybody.

Disclosures

These are my disclosures.

Agenda

This is the agenda.  We will have three scientific presentations and two sessions on clinical cases, where you will be able to vote. 

The briefing room: designing effective combination treatments for breast cancer

The briefing room: designing effective combination treatments for breast cancer

This is just to introduce the next, different presentation.  In fact, today we will be addressing three different questions.  Two questions are clinical and will address what are the unmet medical needs in HER2+ breast cancer, and these will be covered by Dr Cameron, who will discuss first the definition of HER2 breast cancer and the recent advances in the field, including all the targeted therapies.  Then we will discuss the unmet medical needs in HR+ breast cancer and, again, we will discuss the standard of care and the new targeted therapies that are now included in our treatment.  We will also have one presentation which will be more focused on biology and new mechanisms of action for the drug.

I will hand the microphone to David Cameron.  The first presentation is about HER2+ advanced breast cancer and the question he will specifically address is how the hormone receptor status affects treatment response in HER2+ breast cancer.